SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending as cannabis stocks react to speculation around potential federal policy changes, including the possibility of the Trump administration reclassifying marijuana, which could ease restrictions and provide tax benefits to cannabis companies. Community members are actively discussing potential entry points, trading strategies around options, and the possible impact on specific companies within the sector. Some caution against hype, noting previous false starts, while others express optimism for substantial gains if rescheduling occurs.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

$YEE is trending as community members rally around its potential within the Ethereum ecosystem, citing a unique narrative and strong community-driven momentum. Many believe $YEE is poised for a significant breakout, drawing comparisons to past meme coin successes and highlighting its potential for substantial growth. Enthusiasts are actively encouraging others to 'study' $YEE and join the movement, emphasizing its connection to the resurgence of ETH.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending as traders discuss potential holiday season tailwinds and marketplace expansion. Bullish sentiment is fueled by actionable trade alerts and technical analysis pointing to constructive intraday structure. Community members are also weighing factors like the stock's valuation and potential impact from AI initiatives.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CRWV is trending due to a convertible note offering, sparking community debate about the company's debt and future prospects. While some investors express concern over potential dilution and financial health, others view the offering as a strategic move for long-term growth in the AI cloud sector. Discussions also revolve around CRWV's competitive positioning and potential impact from broader industry news, like Oracle's earnings.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to a new partnership with Google involving AI data centers in space, sparking community excitement about the potential for new revenue streams and growth beyond satellite imagery. Bullish sentiment is fueled by analysts raising price targets and institutions increasing their positions, with some viewing the company as undervalued and poised for significant gains. Discussions also revolve around the impact of this development on the broader space sector.

ONDO is a DeFi primitive that enables users to originate risk-isolated, fixed yield loans backed by yield-generating crypto-assets. It's unique because it's a permissionless protocol that allows users to interact on a peer-to-pool basis with no intermediaries.

Ondo

ONDO is trending as the community discusses its potential in the tokenized real-world asset (RWA) space and upcoming catalysts. Speculation surrounds possible integrations with traditional finance, including potential partnerships with BlackRock and the launch of tokenized stocks. Some traders are closely watching a large token unlock event in January 2026.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending as speculation mounts around potential marijuana rescheduling following reports of a possible executive order. Community discussions revolve around the timing and impact of the announcement, with some expecting significant gains and a short squeeze. The stock is seeing increased interest as investors weigh the potential benefits of eased regulations for the cannabis sector.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Cola (KO) is trending as investors discuss a leadership transition with Henrique Braun named as the next CEO in 2026. While some view the change as unlikely to cause volatility, others are analyzing the stock's technicals, with community chatter focused on potential shakeouts and key support levels. Some traders are eyeing potential bullish reversals given oversold conditions, while others express frustration with the stock's price action and debate its premium valuation.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as a potentially disruptive force in the blockchain space, with community members highlighting its impressive transaction speeds and focus on compliance, attracting interest from traditional finance. Discussions emphasize Keeta's role as a complementary infrastructure, not a competitor, to existing blockchains.  Its connections to established entities like Stripe add to its appeal, though some express skepticism, calling it a 'shitcoin'.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos' ATOM crypto is gaining attention due to community discussions surrounding tokenomics changes and comparisons with emerging Layer 1 protocols like Keeta, which boasts impressive transaction speeds and compliance-focused architecture. Community members are weighing ATOM's established interoperability against the potential of newer platforms to disrupt global financial infrastructure, with the token's redesign aimed to improve value accrual. Despite some bearish sentiment, Cosmos' pioneering role in blockchain communication keeps it relevant amid the evolving landscape of Layer 1 solutions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros (NASDAQ:OMER) Trading Down 5.1% - Here's What Happened

Omeros (NASDAQ:OMER) Stock Price Down 5.1% - What's Next...

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports...

Omeros (NASDAQ:OMER) Stock Price Up 8.2% - Still a Buy?

Omeros (NASDAQ:OMER) Trading 8.2% Higher - What's Next...

Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Monday...

<ul class="summary-bullets"><li>Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.</li><li>The company retired its senior loan and expects the remaining cash to extend its runway.</li><li>Traders say the FDA decision on Narsoplimab is now the key market catalyst.</li></ul><p>Omeros Corporation&nbsp;(OMER) said on Monday it has completed its asset sale and licensing agreement with Novo Nordisk for Zaltenibart, an experimental drug being developed for rare immune-related blood and kidney disorders. The transaction includes up to $2.1 billion in potential payments.</p><p>OMER stock traded in the green at the time of writing.&nbsp;</p><h2 class="st-heading-2"><strong>Terms Of The Deal</strong></h2><p>Omeros received $240 million upfront at closing and could earn up to $340 million in early milestones. The agreement grants Novo Nordisk global rights to Zaltenibart and its intellectual property, with total potential value reaching $2.1 billion through future development and commercial milestones. Omeros will also receive tiered royalties on net sales.</p><h2 class="st-heading-2"><strong>Immune Drug Targets Severe Rare Diseases</strong></h2><p>Zaltenibart, formerly OMS906, is a clinical-stage monoclonal antibody that blocks MASP-3, the immune trigger that switches on the alternative complement pathway. The drug is designed to calm an overactive immune response while preserving the body’s main infection-fighting mechanisms. Potential applications include paroxysmal nocturnal hemoglobinuria and several complement-driven kidney disorders. Novo Nordisk said the acquisition strengthens its position in rare immunological diseases.</p><h2 class="st-heading-2"><strong>Upfront Proceeds Slash Debt And Extend Cash Runway</strong></h2><p>Omeros used part of the upfront payment to fully repay its $67.1 million senior secured term loan, including premiums and interest, resulting in the release of all related covenants. The company expects remaining proceeds to cover repayment of its $17.1 million 2026 Convertible Notes and fund more than a year of operations, including preparations for a potential U.S. launch of its MASP-2 inhibitor Narsoplimab. The company continues to advance additional complement-system candidates, including OMS1029 and OMS527.</p><h2 class="st-heading-2"><strong>Stocktwits Users Warn Of FDA-Driven Swings</strong></h2><p>On Stocktwits, Omeros drew ‘bullish’ retail sentiment with ‘normal’ message volume, while Novo Nordisk saw ‘bearish’ sentiment on ‘low’ volume.</p><figure class="image"><img style="aspect-ratio:971/144;" src="https://news.stocktwits-cdn.com/omer_ss_png_4011ca93db.webp" alt="omer ss.png" width="971" height="144"><figcaption>OMER sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:970/144;" src="https://news.stocktwits-cdn.com/nvo_ss_png_d0f2e79132.webp" alt="nvo ss.png" width="970" height="144"><figcaption>NVO sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><p>One user noted that the announcement appeared mostly priced in around $10 and said the stock now hinges on a potential FDA approval for Zaltenibart due Dec.26, calling it a "pure binary event" that could swing shares 30%–50% either way over the next few weeks.</p><p><stembedurl>https://stocktwits.com/WinstonWolfff/message/637795055</stembedurl></p><p>Another user said, “This deal was known for a long time already. What did you expect? Narsoplimabs FDA approval this month is the moneyball.”&nbsp;</p><p><stembedurl>https://stocktwits.com/Iceman89/message/637792822</stembedurl></p><p><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has declined nearly 2% so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> fell about 42% over the same period.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Equity

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906...

Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened...

Omeros (NASDAQ:OMER) Shares Down 5.6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 5.6% - Here's What Happened...

Omeros (NASDAQ:OMER) Stock Price Up 8.1% - Time to Buy?

Omeros (NASDAQ:OMER) Shares Up 8.1% - Here's What Happened...

D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER)

D. Boral Capital reiterated a "buy" rating and set a $36.00 target price on shares of Omeros in a research note on Friday...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Current Price	$10.15
Prev Close	$10.59
Open	$10.61
Dividend Yield	0.00%
50-Day Moving Average	$7.94
Beta	1.42
Avg. Volume	1.73M
PE Ratio	-5.03

52-Week High	$13.60
52-Week Low	$2.95
Market Capitalization	$750.84M
EPS (Annual)	-$2.70
Price to Book	-3.23
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp